Orders -9%, sales +10% vs. ABGSCe EBIT EUR 3m (vs. ABGSCe 2m), for a margin of 7% Profitability impr...
Sales -3%, EBITA +1% vs. ABGSCe, book-to-bill 0.99x Expects decline to decelerate from here, return ...
Redeye states that the Q3 report was solid, with ad revenues returning to y/y growth, while recurrin...
Redeye updated its forecast and valuation following the Q3 report, which showed strong ARR growth (i...
CapMan's Management company business turnover (excluding carried interest) grew 16% y/y in Q3, suppo...
Redeye provides a research update following Catella's Q3 2024 report.
Redeye provides an update following Optomed’s Q3 report.
We lower 2024E sales by ~4% and adjusted EBIT by 12%, driven by Germany, while we keep our estimates...
56% incre. EBITDA margin in Q3 highlights the scalability Increased confidence in positive EBIT in 2...
Nettoomsättningen för det tredje kvartalet uppgick till 0,93 MSEK (0,83), vilket var en ökning om 8,...
20% revenue beat driven by high watch sales, EBITDA 66% above Opex was above, but likely due to extr...
Resultatmässigt hade vi räknat med något lägre vinst än Q3 ifjol men minskningen var större än förvä...
Administer’s Q3 report was in line with expectations.
Suominen had some production issues in Q3, and even if those no longer bother valuation begins to lo...
CapMan’s Q3 results were below our and consensus expectations.
Paper EBITDA PLN 49m, above ABGSCe PLN 47m Group EBITDA beat driven mainly by Paper Outlook remains ...
Redeye provides its initial take on Mentice’s Q3 2024 report, which came in broadly below our estima...
Redeye sees a Q3 report on the soft side from Transtema.
Redeye provides its initial take on Acarix’s Q3 report, which showed revenues falling short of estim...
EBITDA +6% vs ABGSC and EBIT turned positive in Q3 We expect consensus to lift 2024 EBITDA by 10-15%...
